Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA is a paper indexed in PICO Portal from OpenAlex.
How many citations does Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA have?
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA has 26 citations in the OpenAlex counts PICO Portal stores.
When was Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA published?
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA has 2023 year in the PICO Portal index.
What is the open-access status of Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA?
Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA has closed oa status in the PICO Portal index.
What is the DOI of Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA?
The DOI for Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA is on the source record.
What is the PMID of Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA?
The PMID for Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA is on the source record.
What is the OpenAlex record for Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA?
The OpenAlex for Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA is on the source record.